Payment overview · 2025
General Payments
$204.78
13 reported records · 8 companies
Healthcare provider profile · identity verified
Vedat Obuz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TRENTON, NJ · NPI 1255385233
Verified facts
What the public records show
CMS Open Payments records show Vedat Obuz, MD received $204.78 in general payments during 2025 across 13 reported records.
Pharming Healthcare, Inc. accounted for 41.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $84.20 | 41.1% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.25 | 16.2% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $15.83 | 7.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.77 | 7.2% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $14.74 | 7.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.49 | 7.1% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $13.80 | 6.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.70 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $204.78 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $84.20 | 5 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 396 | 115 |
| Metformin Hcl | Metformin Hcl | 372 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 245 | 77 |
| Omeprazole | Omeprazole | 232 | 72 |
| Diclofenac Sodium | Diclofenac Sodium | 200 | 85 |
| Gabapentin | Gabapentin | 198 | 66 |
| Ibuprofen | Ibuprofen | 184 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 40 |
| Montelukast Sodium | Montelukast Sodium | 158 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 52 |
| Lisinopril | Lisinopril | 142 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 39 |
| Furosemide | Furosemide | 109 | 45 |
| Glimepiride | Glimepiride | 109 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 32 |
| Losartan Potassium | Losartan Potassium | 108 | 26 |
| Enalapril Maleate | Enalapril Maleate | 103 | 29 |
| Meloxicam | Meloxicam | 95 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 93 | 46 |
| Potassium Chloride | Potassium Chloride | 89 | 34 |
| Azithromycin | Azithromycin | 85 | 64 |
| Levofloxacin | Levofloxacin | 84 | 63 |
| Clotrimazole | Clotrimazole | 83 | 44 |
| Prednisone | Prednisone | 81 | 45 |
| Carvedilol | Carvedilol | 80 | 30 |
| Famotidine | Famotidine | 73 | 28 |
| Trazodone Hcl | Trazodone Hcl | 70 | 25 |
| Eliquis | Apixaban | 67 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 20 |
| Allopurinol | Allopurinol | 63 | 18 |
| Januvia | Sitagliptin Phosphate | 59 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 18 |
| Sertraline Hcl | Sertraline Hcl | 59 | 16 |
| Donepezil Hcl | Donepezil Hcl | 58 | 20 |
| Metformin Hcl Er | Metformin Hcl | 58 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 14 |
| Repaglinide | Repaglinide | 56 | 14 |
| Jardiance | Empagliflozin | 54 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 14 |
| Naproxen | Naproxen | 53 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 53 | 23 |
| Glipizide Er | Glipizide | 52 | 13 |
| Lorazepam | Lorazepam | 52 | 14 |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 50 | 18 |
| Methylprednisolone | Methylprednisolone | 49 | 45 |
| Mupirocin | Mupirocin | 49 | 34 |
| Ketoconazole | Ketoconazole | 46 | 15 |
| Bupropion Xl | Bupropion Hcl | 45 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 43 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 38 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 14 |
| Ondansetron Odt | Ondansetron | 40 | 18 |
| Dutasteride | Dutasteride | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 18 |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 34 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | 13 |
| Meclizine Hcl | Meclizine Hcl | 32 | 21 |
| Ammonium Lactate | Ammonium Lactate | 31 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Lactulose | Lactulose | 30 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | 13 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Baclofen | Baclofen | 29 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 24 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 11 |
| Prednisolone | Prednisolone | 27 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Fluconazole | Fluconazole | 26 | 13 |
| Glipizide | Glipizide | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 22 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | 15 |
| Topiramate | Topiramate | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | 16 |
| Simvastatin | Simvastatin | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 12 |
| Tramadol Hcl | Tramadol Hcl | 20 | 17 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 18 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 19 | 13 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 13 | 12 |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $204.78 · 13 records | Pharming Healthcare, Inc. | Attruby, BEXSERO, GVOKE HYPOPEN, Haegarda, Korlym, MOUNJARO, PEDIARIX, RUCONEST, WAKIX, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error